Contineum Therapeutics, Inc. CTNM PHARMA
Company Overview
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +129.35% |
| 6 Months: | +17.73% |
| 3 Months: | +38.25% |
| 1 Month: | +5.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CTNM Contineum Therapeutics, Inc. PHARMA | 15.94 | -9.27 | $525.36M | 0.00% | -25.50% | -28.00% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 50.00M | 0 | - | 0 | 0 | - | - | - | - | - |
| Operating Income | -5.12M | 38.94M | -8.07M | -9.93M | -10.94M | -12.97M | -18.11M | -17.90M | -14.93M | -16.90M | -17.43M |
| Net Income | -4.82M | 41.56M | -6.25M | -8.42M | -9.01M | -10.27M | -15.99M | -16.04M | -12.79M | -14.46M | -15.15M |
| Diluted EPS | - | 0.84 | -2.69 | - | -0.39 | -0.40 | -0.62 | -0.62 | - | -0.39 | -0.40 |
| R&D Expense | 3.63M | 9.46M | 6.50M | 7.78M | 7.90M | 9.73M | 13.71M | 14.06M | 10.99M | 11.65M | 12.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 50.00M | 0 | - |
| Operating Income | 16.08M | -50.89M | -68.06M |
| Net Income | 22.72M | -42.26M | -59.98M |
| Diluted EPS | 0.08 | -2.18 | -2.17 |
| R&D Expense | 27.60M | 38.42M | 51.52M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 130.39M | 212.85M | 276.64M |
| Total Equity | -93.21M | -67.94M | 198.07M | 260.99M |
| Cash & Equivalents | - | 15.53M | 21.94M | 75.60M |
| Total Liabilities | - | 5.70M | 14.78M | 15.65M |
| Current Liabilities | - | 5.48M | 9.97M | 9.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 19.35M | -32.84M | -55.31M |
| Investing Cash Flow | -65.57M | -69.74M | -3.71M |
| Financing Cash Flow | 56.18M | 109.00M | 112.69M |
| Capital Expenditure | -414.00K | -514.00K | -231.00K |
| Free Cash Flow | 18.93M | -33.36M | -55.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | 32.2% | - | - |
| Net Margin % | 45.4% | - | - |
| ROE % | -33.4% | -21.3% | -23.0% |
| ROCE % | 12.9% | -25.1% | -25.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 8.62% | 2.84M | $38.44M |
| 2 | Jupiter Topco LLC | 8.30% | 2.73M | $37.00M |
| 3 | Blackrock Inc. | 6.26% | 2.06M | $27.93M |
| 4 | Johnson & Johnson | 6.01% | 1.98M | $26.78M |
| 5 | Franklin Resources, Inc. | 5.58% | 1.84M | $24.88M |
| 6 | Balyasny Asset Management LP | 4.62% | 1.52M | $20.60M |
| 7 | Vanguard Capital Management LLC | 4.01% | 1.32M | $17.88M |
| 8 | Perceptive Advisors Llc | 3.81% | 1.26M | $16.99M |
| 9 | FMR, LLC | 3.16% | 1.04M | $14.07M |
| 10 | Millennium Management Llc | 2.83% | 931.71K | $12.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CTNM
Carmine Stengone to sell 2,500 Contineum (CTNM) shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQR3owdmdhR1ViLU5PNzFRTS1MLUY1dVZ0bHJ5b0RleFdDVFZTZFB0ZTVEc1dhcy0yN01yeXZoSlVaZU1XYjdTRldZVEVScXVVMUp2cUZQS2NvaWR3bWNhLUR0UnRQVm53VzZYTVFIT0FCbm0xNndCbFlOWE5YYUJHVE51ZEcxTWVOSnctWG…
Contineum (CTNM) CEO sells shares under preset plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQWUdQOTJjNC04aXdBUFNhY1pKMWpWQ0h0M1lrcUlVQ0ZZczJTVGotbVVUQWVyck9kb3FGeHdwSmRrRXAyR19fQThQOVJiQTcwOXNCTURqWnYwM0pya0N3U09rYVpHVVhPWC0yRXVmWG4wOTJNUDVKSFFDZTVKOFR6QmdLdnEwWHEtcEhrZm…
Technical Reactions to CTNM Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQSEdpcHdtQlpDbzhBN0pRMy1kZ2d5R3F4dHd0QzRXRjlORXFFdlAtalFONUY0bnVEdVlYa2huZ0dxdFlLYkNCMWp0WGlrTkVubGdsVUVoR3hhSEdHYzQxMHdXZVQwWUdsaHhoWUU2S1Z1d2VpYVY2WU8zNFRIaENnYmdHYUVkNEltUUpDaW…
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNSVFZT3hwSjU5MU4teWx6YU1ycVNCeTVKWm1ydU1PcFdkMklPRXQ0ZVZRTzQ1SlJyenZxRllaYUZPWE8xdTUzTm95N1VvUlJJWnZFTFBybjhGckQxRlNKSmhhdVVycHZ6VTA0d0h2RjZfSmlCYnBaQlByN0tRcVREMlFBeVdtU0hPWjlpVG…
Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOVm8zTTRjMnlQeDhlTzJZRk55OEd5YTZWMHFpWjYxZ1hYcENTTENOS1BLX2wxTldvdi1uTTJoOU0wWXJORWdJbHQ4cnUxVkVVWlR3eW1RVFVrZDlJbDlDNXBOOUUxTG9kNHh1SmFGZUdhQkQ3ektsV3JzMTVLclduUFV6OWFkQW1DUDMxX1…
CTNM Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE92MjFCeFk3S1QyWFhZWWFRN2lUTGFVbVdqTVR3b2hKQXF5MC1kNnRmdGUzVlpYZm9xU05SWkE0MGZJbEhFYlpsQ3NseVRoRC1HT3JmVzRocFg1bmg5WFpHSXZrWXlvdU9UR3dsQ0hCZWRGQ3hIVmRIYTNn?oc=5" target="_blank">CTN…
CTNM — Frequently Asked Questions
What is the current share price of Contineum Therapeutics, Inc. (CTNM)?
As of 2026-09-19 21:16 PDT, Contineum Therapeutics, Inc. (CTNM) trades at $15.94 on NasdaqGS. Its 52-week range is $6.95 to $17.57.
What is the market capitalisation of CTNM?
Contineum Therapeutics, Inc. (CTNM) has a market capitalisation of $525.36M on NasdaqGS.
What is the P/E ratio of CTNM?
CTNM trades at a trailing price-to-earnings (P/E) ratio of -9.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.38.
What is the return on equity (ROE) of CTNM?
CTNM has a return on equity (ROE) of -28.00%. Its return on capital employed (ROCE) is -25.50%.
Is CTNM a good stock to buy?
This page provides a data-driven analysis of Contineum Therapeutics, Inc. (CTNM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.